Can I Take Melatonin with Dayvigo (Lemborexant)?

What Is Dayvigo and Why Do Women Use It?

Dayvigo is the brand name for lemborexant, a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by trouble falling asleep, staying asleep, or both. It works differently from older sleep drugs: instead of globally suppressing brain activity, it blocks orexin receptors OX1R and OX2R, quieting the wake-promoting signals that keep you alert. Think of it as turning off the "stay awake" switch rather than flooding the brain with a sedative.

Women are disproportionately affected by insomnia. Epidemiological data from the CDC show that women report insomnia symptoms at roughly 1.4 times the rate of men, a gap driven partly by hormonal fluctuations across the menstrual cycle, pregnancy, postpartum sleep disruption, and the vasomotor and sleep-architecture changes of perimenopause and menopause. Dayvigo is prescribed across all of these life stages, though the evidence base is concentrated in general adult populations with limited sex-stratified reporting.

How Lemborexant Affects Women's Sleep Architecture

Sleep architecture shifts across the female reproductive lifespan. Progesterone has mild sedative properties through GABA-A receptor modulation, which means sleep quality often dips in the follicular phase (low progesterone) and around menstruation. In perimenopause, dropping estradiol levels disrupt thermoregulation and REM sleep continuity. Lemborexant in the SUNRISE-1 and SUNRISE-2 trials demonstrated significant improvements in sleep onset latency and wake after sleep onset versus placebo and versus zolpidem. Neither trial published sex-stratified subgroup results for efficacy, which is a notable evidence gap (see rule W6 note below).

Evidence gap disclosure: The SUNRISE trials enrolled both sexes but did not publish female-specific efficacy or pharmacokinetic subanalyses in the primary papers. What we know about sex differences in lemborexant comes primarily from the FDA pharmacology review, which noted that females showed modestly higher maximum plasma concentrations (Cmax) compared to males at equivalent doses, likely reflecting lower lean body mass and differences in CYP3A4 activity. This means the 10 mg dose may carry proportionally more sedation risk in women than the same dose in men.

Life Stages Where Dayvigo Is Most Commonly Prescribed

• Reproductive years: Insomnia linked to premenstrual syndrome, PMDD, or hormonal IUD-related cycle changes
• Perimenopause: Night sweats fragment sleep; DORAs are increasingly used as the preferred non-hormonal pharmacologic option per The Menopause Society 2023 position statement
• Postpartum: Fragmented sleep with a newborn creates pressure to use sleep aids, though evidence for DORAs postpartum is minimal
• Post-menopause: Chronic insomnia rates rise after menopause; lemborexant's lack of rebound insomnia on discontinuation makes it attractive for long-term use

What Is Melatonin and How Does It Work?

Melatonin is a pineal hormone that signals darkness to the brain, shifting circadian timing and modestly reducing sleep latency. It is available in the US without a prescription. The catch is that American OTC products typically contain 5 to 10 mg per dose, while the most rigorous meta-analyses support doses of 0.5 to 3 mg for circadian entrainment. Higher doses saturate melatonin receptors without proportional benefit and extend into the next morning, potentially compounding daytime sedation from any co-prescribed sleep medication.

Melatonin acts primarily at MT1 and MT2 receptors in the suprachiasmatic nucleus. It does not share a receptor class with lemborexant. That means there is no pharmacokinetic interaction: melatonin does not inhibit or induce CYP3A4 at clinically relevant doses, so it does not meaningfully change lemborexant's plasma levels.

The Pharmacodynamic Overlap That Matters

Both melatonin and lemborexant reduce alertness and promote sleep onset, through entirely different mechanisms, but the net CNS effect is additive. If you take a 10 mg lemborexant dose and add a 10 mg melatonin supplement (a combination sold in many pharmacy aisles), you are stacking a potent DORA against a supraphysiological dose of a sedating neurohormone. The result is greater residual sedation the following morning, a higher risk of parasomnias such as sleep-driving (already listed in the lemborexant prescribing information), and impaired psychomotor performance on tasks like driving.

No head-to-head randomized trial has examined lemborexant plus melatonin co-administration in women specifically. The interaction reasoning is mechanistic and extrapolated from studies of other DORA-plus-sedating-supplement combinations. That extrapolation is reasonable and clinically accepted, but the direct data do not exist yet.

The Glucose and Metabolic Angle: Why This Matters for Women with PCOS or Prediabetes

This is a section you will not find in most basic interaction checkers. Melatonin has a clinically significant effect on glucose metabolism that is especially relevant for women.

A large Mendelian randomization study published in Nature Medicine (2022) found that higher melatonin receptor 1B (MTNR1B) signaling is associated with higher fasting glucose and increased type 2 diabetes risk, particularly in people carrying the MTNR1B rs10830963 risk allele. The prevalence of this variant is approximately 30% in European-ancestry populations.

Women with PCOS already have baseline insulin resistance. PCOS affects 8 to 13% of women of reproductive age globally and is the leading cause of anovulatory infertility. Adding a high-dose melatonin supplement nightly may worsen overnight insulin sensitivity in a subset of these women, independent of any interaction with lemborexant.

Practical Glucose Monitoring Advice

If you have PCOS, prediabetes, or are postpartum (a period of insulin resistance in its own right), and you want to use melatonin alongside Dayvigo:

• Use the lowest effective melatonin dose, meaning 0.5 mg to 1 mg, not the 10 mg tablet from the pharmacy shelf
• Time melatonin 30 to 60 minutes before your target sleep time, not on top of your lemborexant dose
• Ask your clinician to check a fasting glucose or HbA1c at the next visit if you are adding melatonin longer than four weeks
• Women on metformin for PCOS should note that metformin modestly raises endogenous melatonin by reducing its renal clearance, so exogenous supplementation adds on top of an already-elevated baseline

Pharmacokinetics: Does Melatonin Change Lemborexant Blood Levels?

The short answer is no, not in a clinically meaningful way. Lemborexant is metabolized primarily by CYP3A4, and melatonin does not inhibit or induce this enzyme at physiological doses. Melatonin is itself metabolized by CYP1A2 in the liver. These are separate pathways with no significant cross-talk at normal supplement doses.

Where pharmacokinetics does matter for women: oral contraceptives containing ethinyl estradiol are moderate CYP1A2 inhibitors. If you are on a combined OCP and you take melatonin, your melatonin exposure may be higher than expected, potentially enhancing the sedative and glucose effects described above. This is a documented interaction noted in pharmacology literature but rarely flagged in standard drug checkers.

Female-Specific PK Differences with Lemborexant

Per the FDA pharmacology review of the Dayvigo NDA, women had approximately 20 to 25% higher lemborexant AUC and Cmax compared to men after a 10 mg dose, attributed to body composition differences and possible hormonal modulation of CYP3A4. Postmenopausal women on hormone therapy containing estrogen may have slightly altered CYP3A4 activity, though the clinical magnitude of this effect has not been formally quantified for lemborexant specifically.

This female-specific PK difference is the reason the FDA label recommends starting at 5 mg for most patients and reserving 10 mg for those who tolerate the lower dose without adequate benefit. For women, this starting-low principle is especially relevant.

Pregnancy and Lactation Safety

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Lemborexant in Pregnancy

Lemborexant is not recommended during pregnancy. Animal reproductive toxicology studies submitted in the FDA NDA showed adverse fetal effects at exposures above the human therapeutic dose, including decreased fetal body weight and skeletal variations in rats. There are no adequate, well-controlled human studies in pregnant women. The FDA has not assigned a traditional letter category under the post-2015 labeling rule, but the prescribing information states use in pregnancy only if the potential benefit justifies the potential risk, which in practice means it should be avoided.

If you become pregnant while taking lemborexant, contact your prescriber promptly. Do not stop abruptly without guidance if you have been on the medication long-term, but plan a supervised taper.

Contraception Requirements

Lemborexant is not classified as a teratogen requiring mandatory contraception in the same category as medications like isotretinoin or valproate. There is no FDA-mandated REMS program or required contraceptive form. Still, given the absence of human safety data, clinicians at WomanRx advise using reliable contraception if you are sexually active and not actively trying to conceive while on lemborexant.

Melatonin in Pregnancy

Melatonin is not FDA-regulated as a drug and carries no formal pregnancy category. ACOG does not endorse melatonin supplementation in pregnancy given the lack of controlled safety data. Endogenous melatonin rises naturally in late pregnancy and plays a role in fetal circadian programming, so adding exogenous melatonin in supraphysiological doses is theoretically risky, though no large human harm signal has emerged.

Avoid the combination of lemborexant plus melatonin in pregnancy for the simple reason that neither is adequately established as safe, and combining two under-studied compounds in pregnancy is not justified for a non-life-threatening condition.

Lactation

Lemborexant's transfer into human breast milk has not been studied. The FDA label advises that because of the potential for serious adverse reactions in breastfed infants (sedation, respiratory depression), a decision should be made to discontinue breastfeeding or discontinue the drug. If you are postpartum and your insomnia is severe, discuss with your clinician whether a short course is appropriate with a pump-and-discard strategy, or whether cognitive behavioral therapy for insomnia (CBT-I) is a safer first-line option. CBT-I has Level I evidence for insomnia and carries zero lactation risk.

Melatonin is present in breast milk naturally. Adding supplemental melatonin while breastfeeding may increase infant melatonin exposure beyond physiological norms. Infant sedation is a theoretical concern, though documented cases are rare.

Who This Combination Is and Is Not Right For

You Might Be a Candidate for Careful Use of Both

• You are in perimenopause or post-menopause with circadian disruption (early morning waking) on top of sleep maintenance insomnia that Dayvigo addresses
• You are using a very low melatonin dose (0.5 mg) purely for circadian shifting, not as an additional sedative
• You do not have PCOS, prediabetes, or significant insulin resistance
• Your prescriber knows you are taking both and agrees to monitor

This Combination Is Likely Not Right for You If

• You are pregnant or trying to conceive within the next cycle
• You are breastfeeding a newborn
• You have PCOS with insulin resistance and your glucose control is not yet optimized
• You are already on the 10 mg dose of lemborexant and experience next-morning grogginess
• You are taking other CNS depressants, benzodiazepines, opioids, or antihistamines that already compound sedation risk
• You are a shift worker or have job duties requiring early-morning driving or safety-critical attention

How to Use Both Safely If Your Clinician Approves

If after a shared-decision conversation your clinician agrees the combination is appropriate, these steps reduce risk:

Step 1: Use the Lowest Effective Melatonin Dose

Start at 0.5 mg, not 5 or 10 mg. Most American supplement bottles dramatically over-dose relative to the physiologically active range. A 2023 analysis in JAMA found that melatonin content in commercial supplements ranged from 83% below to 478% above the labeled dose, meaning a "3 mg" tablet might deliver anywhere from 0.5 mg to 14 mg.

Step 2: Time Melatonin Before, Not With, Your Dayvigo Dose

Take melatonin 30 to 60 minutes before your target bedtime. Take lemborexant within 30 minutes of your intended sleep time. This slight separation is not large enough to meaningfully reduce the pharmacodynamic overlap, but it does match each drug's optimal timing window rather than creating a concentrated bolus of two sedatives at once.

Step 3: Do Not Drive the Morning After

The FDA prescribing information for Dayvigo already warns against next-morning driving and operating heavy machinery. Adding melatonin extends the window of potential impairment. Allow at least eight full hours after taking both before driving.

Step 4: Tell Every Clinician on Your Team

Sleep aids and supplements are frequently not disclosed to gynecologists, endocrinologists, or fertility specialists. If you are managing PCOS with a reproductive endocrinologist, seeing a menopause specialist, or about to start fertility treatment, they need to know you are on Dayvigo and melatonin. Ovarian stimulation protocols, sedation for egg retrieval, and certain fertility medications can interact with sedating agents.

Step 5: Reassess Every Three Months

Insomnia is not always a permanent condition. Perimenopausal insomnia may improve after hormone therapy stabilizes estradiol. Postpartum insomnia typically resolves as infant sleep consolidates. Set a calendar reminder every three months to ask: do I still need both?

Alternatives to Adding Melatonin to Dayvigo

If your goal in adding melatonin is circadian shifting (jet lag, shift work, delayed sleep phase), there are alternatives worth discussing:

• Low-dose melatonin alone (without Dayvigo) may be sufficient for circadian disorders
• Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for chronic insomnia per the American College of Physicians, with evidence superior to pharmacotherapy for long-term outcomes and no risk profile at all
• Magnesium glycinate at 200 to 400 mg nightly is widely used for sleep and has a favorable safety profile, though the evidence for it as a clinical sleep aid is limited to small trials
• Hormone therapy in perimenopausal and postmenopausal women may address the root cause of sleep disruption. The Menopause Society 2023 position statement supports hormone therapy as effective for vasomotor symptoms and associated sleep disruption in women under 60 who are within 10 years of menopause onset

A Word on the Evidence Gap

Studies examining the combination of DORAs with melatonin in women specifically do not yet exist. The clinical reasoning in this article is built from: the established pharmacodynamic profiles of each agent, female-specific PK data from the FDA label review, melatonin's documented glucose effects in women with MTNR1B variants, and expert consensus. Randomized data on this exact combination in perimenopausal or PCOS-affected women is an area where research is genuinely needed.

That absence of data is not the same as evidence of safety. It is an evidence gap, and your clinical decision should account for it.